

## **Coronavirus disease (COVID-19) updates** <sup>[1]</sup>

**Publish Date:** 2020

Novartis announced today its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response. Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. Novartis is supporting ongoing clinical trial efforts, and will evaluate needs for additional clinical trials.

- Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19.
- Novartis Sandoz division will pursue appropriate regulatory authorizations and, upon approval, will work with stakeholders to determine how best to get this medicine to the patients who need it
- Commitment builds on recently announced USD 20 million Novartis COVID-19 Response Fund, drug discovery and development collaborations and essential medicines price stability
- Novartis encourages industry, governments and international institutions to work together to ensure adequate global access of medications to treat COVID-19 patients

**[Read the full media release](#)** <sup>[2]</sup>

**[Novartis COVID-19 Information Centre](#)** <sup>[3]</sup>

---

**Source URL:** <https://www.sandoz.be/nl/news/coronavirus-disease-covid-19-updates>

### **Links**

[1] <https://www.sandoz.be/nl/news/coronavirus-disease-covid-19-updates>

[2] <https://www.novartis.com/news/media-releases/novartis-commits-donate-130-million-doses-hydroxychloroquine-support-global-covid-19-pandemic-response>

[3] <https://www.novartis.com/coronavirus>